Randomized cross-over trial of short-term water-only fasting: Metabolic and cardiovascular consequences

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 11, 2013, Pages 1050-1057

  Horne, B D ^a,b   Muhlestein, J B ^a,b   Lappe D L ^a,b   May, H T ^a   Carlquist, J F ^a,b   Galenko, O ^a   Brunisholz, K D ^a   Anderson, J L ^a,b  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Caloric restriction; Energy restriction; Erythrocyte; Fasting; FGF 21; Hemoglobin; Human growth hormone

Indexed keywords

BICARBONATE; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 21; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HEPATOCYTE NUCLEAR FACTOR 3BETA; HEPATOCYTE NUCLEAR FACTOR 3GAMMA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; SODIUM; TRIACYLGLYCEROL; WATER;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; GENE EXPRESSION; HEADACHE; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; INTERVENTION STUDY; LONGEVITY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ANIMALIA;

CALORIC RESTRICTION; ENERGY RESTRICTION; ERYTHROCYTE; FASTING; FGF-21; HEMOGLOBIN; HUMAN GROWTH HORMONE;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES; UTAH; WATER; WEIGHT LOSS;

EID: 84887613549     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.09.007     Document Type: Article

References (39)

1. Horne B.D., May H.T., Anderson J.L., Kfoury A.G., Bailey B.M., McClure B.S., et al. Usefulness of routine periodic fasting to lower risk of coronary artery disease among patients undergoing coronary angiography. Am J Cardiol 2008, 102:814-819.
2. Lyon J.L., Wetzler H.P., Gardner J.W., Klauber M.R., Williams R.R. Cardiovascular mortality in Mormons and non-Mormons in Utah, 1969-1971. Am J Epidemiol 1978, 108:357-366.
3. Enstrom J.E. Health practices and cancer mortality among active California Mormons. J Natl Cancer Inst 1989, 81:1807-1814.
4. Horne B.D., Muhlestein J.B., May H.T., Carlquist J.F., Lappé D.L., Bair T.L., et al. Relation of routine, periodic fasting to risk of diabetes mellitus and coronary artery disease among patients undergoing coronary angiography. Am J Cardiol 2012, 109:1558-1562.
5. Zhang L., Rubins N.E., Ahima R.S., Greenbaum L.E., Kaestner K.H. Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab 2005, 2:141-148.
6. Panowski S.H., Wolff S., Aguilaniu H., Durieux J., Dillin A. PHA-4/Foxa mediates diet-restriction-induced longevity of C. elegans. Nature 2007, 447:550-556.
7. Xing C., Cohen J.C., Boerwinkle E. A weighted false discovery rate control procedure reveals alleles at FOXA2 that influence fasting glucose levels. Am J Hum Genet 2010, 86:440-446.
8. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
9. Horne B.D., May H.T., Muhlestein J.B., Ronnow B.S., Lappé D.L., Renlund D.G., et al. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med 2009, 122:550-558.
10. Fontana L., Klein S. Aging, adiposity, and calorie restriction. JAMA 2007, 297:986-994.
11. Hietaniemi M., Jokela M., Rantala M., Ukkola O., Vuoristto J.T., Ilves M., et al. The effect of a short-term hypocaloric diet on liver gene expression and metabolic risk factors in obese women. Nutr Metab Cardiovasc Dis 2009, 19:177-183.
12. Tapsell L., Batterham M., Huang X.F., Tan S.Y., Teuss G., Charlton K., et al. Short term effects of energy restriction and dietary fat sub-type on weight loss and disease risk factors. Nutr Metab Cardiovasc Dis 2010, 20:317-325.
13. Borriello A., Cucciolla V., Della Ragione F., Galletti P. Dietary polyphenols: focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis. Nutr Metab Cardiovasc Dis 2010, 20:618-625.
14. Raffaghello L., Lee C., Safdie F.M., Wei M., Madia F., Bianchi G., et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A 2008, 105:8215-8220.
15. Wan R., Camandola S., Mattson M.P. Intermittent fasting and dietary supplementation with 2-deoxy-D-glucose improve functional and metabolic cardiovascular risk factors in rats. FASEB J 2003, 17:1133-1134.
16. Enstrom J.E., Breslow L. Lifestyle and reduced mortality among active California Mormons, 1980-2004. Prev Med 2008, 46:133-136.
17. Singer G.G., Brenner B.M. Fluid and electrolyte disturbances. Harrison's principles of internal medicine 1998, 269. McGraw-Hill Companies, Inc., New York. A.S. Fauci, E. Braunwald, K.J. Isselbacher, J.D. Wilson, J.B. Martin, D.L. Kasper (Eds.).
18. Singh R., Sirisinghe R.G. Haematological and plasma electrolyte changes after long distance running in high heat and humidity. Singapore Med J 1999, 40:84-87.
19. Spark R.F., Arky R.A., Boulter P.R., Saudek C.D., O'Brian J.T. Renin, aldosterone and glucagon in the natriuresis of fasting. N Engl J Med 1975, 292:1335-1340.
20. Yasaka M., Yamaguchi T., Oita J., Sawada T., Shichiri M., Omae T. Clinical features of recurrent embolization in acute cardioembolic stroke. Stroke 1993, 24:1681-1685.
21. Nadav L., Gur A.Y., Korczyn A.D., Bornstein N.M. Stroke in hospitalized patients: are there special risk factors?. Cerebrovasc Dis 2002, 13:127-131.
22. Gossmann J., Thurmann P., Bachmann T., Weller S., Kachel H.G., Schoeppe W., et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996, 50:973-978.
23. Hojman P., Brolin C., Gissel H., Brandt C., Zerahn B., Pedersen B.K., et al. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009, 4:e5894.
24. Katz O., Stuible M., Golishevski N., Lifshitz L., Tremblay M.L., Gassmann M., et al. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010, 205:87-95.
25. Tuzcu A., Bahceci M., Yilmaz E., Bahceci S., Tuzcu S. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 2004, 36:716-720.
26. Rasic-Milutinovic Z., Perunicic-Pekovic G., Cavala A., Gluvic Z., Bokan L., Stankovic S. The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia 2008, 12:157-161.
27. Khedr E., El-Sharkawy M., Abdulwahab S., Eldin E.N., Ali M., Youssif A., et al. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. Hemodial Int 2009, 13:340-346.
28. Sävendahl L., Underwood L.E. Fasting increases serum total cholesterol, LDL cholesterol, and apolipoprotein B in healthy, nonobese humans. J Nutr 1999, 129:2005-2008.
29. LeBlanc P.J., Obbard M., Battersby B.J., Felskie A.K., Brown L., Wright P.A., et al. Correlations of plasma lipid metabolites with hibernation and lactation in wild black bears Ursus americanus. J Comp Physiol B 2001, 171:327-334.
30. Norrelund H., Nielsen S., Christiansen J.S., Jorgensen J.O.L., Moller N. Modulation of basal glucose metabolism and insulin sensitivity by growth hormone and free fatty acids during short-term fasting. Eur J Endocrinol 2004, 150:779-787.
31. Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. Growth Horm IGF Res 2005, 15:95-122.
32. Rudman D., Feller A.G., Nagraj H.S., Gergans G.A., Lalitha P.Y., Goldberg A.F., et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990, 323:1-6.
33. Liu H., Bravata D.M., Olkin I., Nayak S., Roberts B., Garber A.M., et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007, 146:104-115.
34. Merimee T.J., Pulkkinen A.J., Burton C.E. Diet-induced alterations of hGH secretion in man. J Clin Endocrinol Metab 1976, 42:931-937.
35. Ho K.Y., Veldhuis J.D., Johnson M.L., Furlanetto R., Evans W.S., Alberti K.G.M.M., et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 1988, 81:968-975.
36. Godfrey R.J., Madgwick Z., Whyte G.P. The exercise-induced growth hormone response in athletes. Sports Med 2003, 33:599-613.
37. VanderLaan W.P. Changing concepts on the control of growth hormone secretion in man. Calif Med 1971, 115:38-46.
38. Ahmet I., Wan R., Mattson M.P., Lakatta E.G., Talan M.I. Chronic alternate-day fasting results in reduced diastolic compliance and diminished systolic reserve in rats. J Card Fail 2010, 16:843-853.
39. Anson R.M., Guo Z., de Cabo R., Iyun T., Rios M., Hagepanos A., et al. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci U S A 2003, 100:6216-6220.